FDA Approved Products
4,491 products with lifecycle intelligence, competitive pressure scores, and patent timelines.
CAYSTON
aztreonam
LOE Approaching
Gilead Sciences
INHALATION · FOR SOLUTION
respiratory symptoms in cystic fibrosis (CF) patients with Pseudomonas aeruginosa
2010
NDA30/100
CECLOR
cefaclor
LOE Approaching
Eli Lilly and Company
ORAL · FOR SUSPENSION
the treatment of the following infectionsHaemophilus influenzae+3
1979
NDA30/100
CECLOR
cefaclor
LOE Approaching
Eli Lilly and Company
ORAL · CAPSULE
the treatment of the following infectionsHaemophilus influenzae+3
1979
NDA30/100
CECLOR CD
cefaclor
LOE Approaching
Eli Lilly and Company
ORAL · TABLET, EXTENDED RELEASE
the treatment of the following infectionsHaemophilus influenzae+3
1996
NDA30/100
CEDAX
ceftibuten dihydrate
LOE Approaching
ORAL · FOR SUSPENSION
individuals with mild-to-moderate infections caused by susceptible strains of the designated microorganisms in the specific conditions listed below (see
1995
NDA30/100
CEDAX
ceftibuten dihydrate
LOE Approaching
ORAL · CAPSULE
individuals with mild-to-moderate infections caused by susceptible strains of the designated microorganisms in the specific conditions listed below (see
1995
NDA30/100
CEFAZOLIN AND DEXTROSE
cefazolin sodium
LOE Approaching
B. Braun
INJECTION · INJECTABLE
respiratory tract infections due to Streptococcus pneumoniaeStaphylococcus aureus+15
2000
NDA30/100
CEFEPIME AND DEXTROSE IN DUPLEX CONTAINER
cefepime hydrochloride
LOE Approaching
B. Braun
INJECTION · INJECTABLE
pneumonia (moderate to severe) caused by Streptococcus pneumoniae (including cases associated with concurrent bacteremia)Pseudomonas aeruginosa+5
2010
NDA30/100
CEFEPIME IN PLASTIC CONTAINER
cefepime
LOE Approaching
Baxter
INJECTION · INJECTABLE
2008
NDA30/100
CEFIZOX
ceftizoxime sodium
LOE Approaching
Astellas
INJECTION · INJECTABLE
the treatment of infections due to susceptible strains of the microorganisms listed belowdevelopment of drug-resistant bacteria+5
1983
NDA30/100
CEFIZOX IN DEXTROSE 5% IN PLASTIC CONTAINER
ceftizoxime sodium
LOE Approaching
Astellas
INJECTION · INJECTABLE
the treatment of infections due to susceptible strains of the microorganisms listed belowdevelopment of drug-resistant bacteria+5
1984
NDA30/100
CEFIZOX IN PLASTIC CONTAINER
ceftizoxime sodium
LOE Approaching
Astellas
INJECTION · INJECTABLE
the treatment of infections due to susceptible strains of the microorganisms listed belowdevelopment of drug-resistant bacteria+5
1984
NDA30/100
CEFMAX
cefmenoxime hydrochloride
LOE Approaching
INJECTION · INJECTABLE
1987
NDA30/100
CEFOBID
cefoperazone sodium
LOE Approaching
Pfizer
INJECTION · INJECTABLE
1982
NDA30/100
CEFOBID IN PLASTIC CONTAINER
cefoperazone sodium
LOE Approaching
Pfizer
INJECTION · INJECTABLE
1986
NDA30/100
CEFOTAN
cefotetan
LOE Approaching
R-Pharm US
INJECTION · INJECTABLE
incidence of certain postoperative infections in patients undergoing surgical procedurespotentially contaminated (e
1985
NDA30/100
CEFOTAN IN PLASTIC CONTAINER
cefotetan disodium
LOE Approaching
R-Pharm US
INJECTION · INJECTABLE
incidence of certain postoperative infections in patients undergoing surgical procedurespotentially contaminated (e
1993
NDA30/100
CEFOTAXIME AND DEXTROSE 2.4% IN PLASTIC CONTAINER
cefotaxime sodium
LOE Approaching
B. Braun
INJECTION · INJECTABLE
2004
NDA30/100
CEFOTAXIME AND DEXTROSE 3.9% IN PLASTIC CONTAINER
cefotaxime sodium
LOE Approaching
B. Braun
INJECTION · INJECTABLE
2004
NDA30/100
CEFOTETAN AND DEXTROSE IN DUPLEX CONTAINER
cefotetan disodium
LOE Approaching
B. Braun
INJECTION · INJECTABLE
incidence of certain postoperative infections in patients undergoing surgical procedurespotentially contaminated (e
2007
NDA30/100
CEFOXITIN AND DEXTROSE IN DUPLEX CONTAINER
cefoxitin sodium
LOE Approaching
B. Braun
INJECTION · INJECTABLE
lower respiratory tract infectionsincluding pneumonia+34
2006
NDA30/100
CEFPIRAMIDE SODIUM
cefpiramide sodium
LOE Approaching
Thayer Medical
INJECTION · INJECTABLE
1989
NDA30/100
CEFTIN
cefuroxime axetil
LOE Approaching
GSK
ORAL · FOR SUSPENSION
older) with mild-to-moderate pharyngitis/tonsillitis caused by susceptible strains of Streptococcus pyogenesHaemophilus influenzae (including β-lactamase–producing strains)+27
1994
NDA30/100
CEFTIN
cefuroxime axetil
LOE Approaching
GSK
ORAL · TABLET
older) with mild-to-moderate pharyngitis/tonsillitis caused by susceptible strains of Streptococcus pyogenesHaemophilus influenzae (including β-lactamase–producing strains)+27
1987
NDA30/100